Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Dec 24

PMID 34944747

Citations 34

Authors

Chiara Colarusso

Angelantonio Maglio

Michela Terlizzi

Carolina Vitale

Antonio Molino

Aldo Pinto

Alessandro Vatrella

Rosalinda Sorrentino

Affiliations

Soon will be listed here.

Abstract

Purpose: SARS-CoV-2 infection induces in some patients a condition called long-COVID-19, herein post-COVID-19 (PC), which persists for longer than the negative oral-pharyngeal swab. One of the complications of PC is pulmonary fibrosis. The purpose of this study was to identify blood biomarkers to predict PC patients undergoing pulmonary fibrosis.

Patients And Methods: We analyzed blood samples of healthy, anti-SARS-CoV-2 vaccinated (VAX) subjects and PC patients who were stratified according to the severity of the disease and chest computed tomography (CT) scan data.

Results: The inflammatory C reactive protein (CRP), complement complex C5b-9, LDH, but not IL-6, were higher in PC patients, independent of the severity of the disease and lung fibrotic areas. Interestingly, PC patients with ground-glass opacities (as revealed by chest CT scan) were characterized by higher plasma levels of IL-1α, CXCL-10, TGF-β, but not of IFN-β, compared to healthy and VAX subjects. In particular, 19 out of 23 (82.6%) severe PC and 8 out of 29 (27.6%) moderate PC patients presented signs of lung fibrosis, associated to lower levels of IFN-β, but higher IL-1α and TGF-β.

Conclusions: We found that higher IL-1α and TGF-β and lower plasma levels of IFN-β could predict an increased relative risk (RR = 2.8) of lung fibrosis-like changes in PC patients.

Citing Articles

A blood-based mRNA signature distinguishes people with Long COVID from recovered individuals.

Missailidis D, Ebrahimie E, Dehcheshmeh M, Allan C, Sanislav O, Fisher P Front Immunol. 2024; 15:1450853.

PMID: 39691709 PMC: 11649547. DOI: 10.3389/fimmu.2024.1450853.

Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era.

Wang Z, Li L, Yang S, Li Z, Zhang P, Shi R Front Microbiol. 2024; 15:1470953.

PMID: 39444690 PMC: 11497467. DOI: 10.3389/fmicb.2024.1470953.

The Diagnostic and Predictive Value of Biomarkers for Pulmonary Fibrosis in Patients with Coronavirus Disease 2019.

Lv J, Liping C, Huaying W J Glob Infect Dis. 2024; 16(2):45-53.

PMID: 39081507 PMC: 11286082. DOI: 10.4103/jgid.jgid_150_23.

Pathophysiological, immunological, and inflammatory features of long COVID.

Bohmwald K, Diethelm-Varela B, Rodriguez-Guilarte L, Rivera T, Riedel C, Gonzalez P Front Immunol. 2024; 15:1341600.

PMID: 38482000 PMC: 10932978. DOI: 10.3389/fimmu.2024.1341600.

Cyclosporine A in hospitalized COVID-19 pneumonia patients to prevent the development of interstitial lung disease: a pilot randomized clinical trial.

Cobo-Ibanez T, Mora Ortega G, Sanchez-Piedra C, Serralta-San Martin G, Thuissard-Vasallo I, Lores Gutierrez V Sci Rep. 2024; 14(1):3789.

PMID: 38360855 PMC: 10869838. DOI: 10.1038/s41598-024-54196-5.

References

Callard F, Perego E . How and why patients made Long Covid. Soc Sci Med. 2020; 268:113426. PMC: 7539940. DOI: 10.1016/j.socscimed.2020.113426. View

Terlizzi M, Molino A, Colarusso C, Donovan C, Imitazione P, Somma P . Activation of the Absent in Melanoma 2 Inflammasome in Peripheral Blood Mononuclear Cells From Idiopathic Pulmonary Fibrosis Patients Leads to the Release of Pro-Fibrotic Mediators. Front Immunol. 2018; 9:670. PMC: 5895962. DOI: 10.3389/fimmu.2018.00670. View

Polidoro R, Hagan R, Santiago R, Schmidt N . Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. Front Immunol. 2020; 11:1626. PMC: 7344249. DOI: 10.3389/fimmu.2020.01626. View

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J . Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020; 370(6515). PMC: 7857407. DOI: 10.1126/science.abd4570. View

Bastard P, Rosen L, Zhang Q, Michailidis E, Hoffmann H, Zhang Y . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020; 370(6515). PMC: 7857397. DOI: 10.1126/science.abd4585. View

Borthwick L . The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin Immunopathol. 2016; 38(4):517-34. PMC: 4896974. DOI: 10.1007/s00281-016-0559-z. View

Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-1034. PMC: 7270045. DOI: 10.1016/S0140-6736(20)30628-0. View

Buttmann M, Merzyn C, Rieckmann P . Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol. 2004; 156(1-2):195-203. DOI: 10.1016/j.jneuroim.2004.07.016. View

Pan F, Ye T, Sun P, Gui S, Liang B, Li L . Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020; 295(3):715-721. PMC: 7233367. DOI: 10.1148/radiol.2020200370. View

10.

Davis H, Assaf G, McCorkell L, Wei H, Low R, Reem Y . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38:101019. PMC: 8280690. DOI: 10.1016/j.eclinm.2021.101019. View

11.

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

12.

Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio M . Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021; 20(3):102763. DOI: 10.1016/j.autrev.2021.102763. View

13.

Tale S, Ghosh S, Meitei S, Kolli M, Garbhapu A, Pudi S . Post-COVID-19 pneumonia pulmonary fibrosis. QJM. 2020; 113(11):837-838. PMC: 7454835. DOI: 10.1093/qjmed/hcaa255. View

14.

Young Chung J, Thone M, Kwon Y . COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2020; 170:1-25. PMC: 7759095. DOI: 10.1016/j.addr.2020.12.011. View

15.

Nigdelioglu R, Hamanaka R, Meliton A, OLeary E, Witt L, Cho T . Transforming Growth Factor (TGF)-β Promotes de Novo Serine Synthesis for Collagen Production. J Biol Chem. 2016; 291(53):27239-27251. PMC: 5207151. DOI: 10.1074/jbc.M116.756247. View

16.

Smilowitz N, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman J . C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021; 42(23):2270-2279. PMC: 7928982. DOI: 10.1093/eurheartj/ehaa1103. View

17.

Colarusso C, Terlizzi M, Pinto A, Sorrentino R . A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019. Br J Pharmacol. 2020; 177(21):4866-4872. PMC: 7300552. DOI: 10.1111/bph.15154. View

18.

Malmstrom J, Lindberg H, Lindberg C, Bratt C, Wieslander E, Delander E . Transforming growth factor-beta 1 specifically induce proteins involved in the myofibroblast contractile apparatus. Mol Cell Proteomics. 2004; 3(5):466-77. DOI: 10.1074/mcp.M300108-MCP200. View

19.

Jalkanen J, Hollmen M, Jalkanen S . Interferon beta-1a for COVID-19: critical importance of the administration route. Crit Care. 2020; 24(1):335. PMC: 7290144. DOI: 10.1186/s13054-020-03048-5. View

20.

DiPiazza A, Graham B, Ruckwardt T . T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochem Biophys Res Commun. 2020; 538:211-217. PMC: 7584424. DOI: 10.1016/j.bbrc.2020.10.060. View